BackMayinglong Pharmaceutical Group , Ltd. Overview
Mayinglong Pharmaceutical Group Co., Ltd.

Mayinglong Pharmaceutical Group , Ltd. Return on Equity

Mayinglong Pharmaceutical Group , Ltd. (600993.SS) has a ROE of 12.95%, above the sector sector average of 11.3%.

Get informed when a big investor buys or sells

+ Follow

ROE

12.95%

Return on Equity

12.95%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Mayinglong Pharmaceutical Group , Ltd. (600993.SS) FAQ

Mayinglong Pharmaceutical Group , Ltd. posts a ROE of 12.95%. That is above the sector sector average of 11.3%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For its sector stocks, a ROE near 11.3% is typical. Mayinglong Pharmaceutical Group , Ltd.'s 12.95% is higher that level. That is roughly 14.7% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Mayinglong Pharmaceutical Group , Ltd.'s ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 12.95%; use YoY and peer views to separate noise from signal.

Context for 600993.SS's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 11.3%), and (3) consistency with growth and profitability. This page covers the first two; Mayinglong Pharmaceutical Group , Ltd.'s other metric pages and overview cover the third.